S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

$1.01
0.00 (0.00%)
(As of 01:58 PM ET)
Today's Range
$0.98
$1.05
50-Day Range
$0.91
$1.61
52-Week Range
$0.83
$11.90
Volume
49,042 shs
Average Volume
127,277 shs
Market Capitalization
$14.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Accelerate Diagnostics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
0.45mentions of Accelerate Diagnostics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$978 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.63) to ($2.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.01 out of 5 stars

Medical Sector

518th out of 939 stocks

Analytical Instruments Industry

13th out of 28 stocks

AXDX stock logo

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

AXDX Stock Price History

AXDX Stock News Headlines

A Preview Of Accelerate Diagnostics's Earnings
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
PAVmed Q4 2024 Earnings Preview
AXDX Apr 2024 2.500 call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Accelerate Declares Q1 2024 Cash Distributions
AXDX Mar 2024 2.500 put
Accelerate Diagnostics Preliminary FY23 Revenue Down
See More Headlines
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AXDX
Employees
179
Year Founded
N/A

Profitability

Net Income
$-62,490,000.00
Net Margins
-472.05%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.75 million
Book Value
($2.25) per share

Miscellaneous

Free Float
9,761,000
Market Cap
$14.72 million
Optionable
Optionable
Beta
0.51
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Jack PhillipsMr. Jack Phillips (Age 58)
    CEO, President & Director
    Comp: $595k
  • Mr. Lawrence Michael Mertz (Age 62)
    Chief Technology Officer
    Comp: $329.23k
  • Mr. David Patience (Age 38)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Ms. Maya Gowri
    Senior VP & Head of Operations
  • Laura Pierson
    Investor Relations Officer
  • Mr. John Meduri
    Chief Strategy Officer
  • Mr. Chris Thode
    Senior Vice President of US Commercial
  • Ms. Rita Boukamel
    Senior VP & Head of EMEA

AXDX Stock Analysis - Frequently Asked Questions

How have AXDX shares performed in 2024?

Accelerate Diagnostics' stock was trading at $3.92 at the beginning of 2024. Since then, AXDX shares have decreased by 73.9% and is now trading at $1.0221.
View the best growth stocks for 2024 here
.

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AXDX earnings forecast
.

How can I listen to Accelerate Diagnostics' earnings call?

Accelerate Diagnostics will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "7585609".

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its quarterly earnings data on Tuesday, November, 9th. The medical research company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($3.50) by $2.00. The medical research company earned $3.12 million during the quarter, compared to analysts' expectations of $3.51 million. During the same quarter last year, the business posted ($3.30) EPS.

When did Accelerate Diagnostics' stock split?

Shares of Accelerate Diagnostics reverse split before market open on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics issued an update on its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $12.1 million-$12.1 million, compared to the consensus revenue estimate of $12.8 million.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Griffin Asset Management Inc. (8.38%), Oracle Investment Management Inc. (0.77%), Citadel Advisors LLC (0.00%), Wolverine Asset Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Ron Price and Steven Reichling.
View institutional ownership trends
.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners